Equities research analysts at BTIG Research started coverage on shares of Carisma Therapeutics (NASDAQ:CARM - Get Free Report) in a report issued on Thursday, Marketbeat reports. The brokerage set a "buy" rating and a $6.00 price target on the stock. BTIG Research's price target indicates a potential upside of 203.03% from the stock's previous close.
Separately, HC Wainwright lowered their price target on shares of Carisma Therapeutics from $11.00 to $9.00 and set a "buy" rating on the stock in a report on Tuesday, April 2nd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $9.00.
Read Our Latest Report on Carisma Therapeutics
Carisma Therapeutics Stock Performance
Shares of NASDAQ CARM traded up $0.07 during trading on Thursday, hitting $1.98. The company had a trading volume of 176,088 shares, compared to its average volume of 156,330. Carisma Therapeutics has a 12 month low of $1.80 and a 12 month high of $9.77. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.06 and a current ratio of 5.06. The firm has a market capitalization of $82.25 million, a P/E ratio of -0.58 and a beta of 0.95. The stock has a 50 day simple moving average of $2.29 and a 200 day simple moving average of $2.71.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CARM. BlackRock Inc. lifted its holdings in shares of Carisma Therapeutics by 1,255.8% in the second quarter. BlackRock Inc. now owns 1,783,238 shares of the company's stock worth $15,639,000 after buying an additional 1,651,714 shares in the last quarter. Vanguard Group Inc. grew its stake in Carisma Therapeutics by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 1,568,761 shares of the company's stock valued at $4,596,000 after acquiring an additional 8,435 shares in the last quarter. Geode Capital Management LLC increased its holdings in Carisma Therapeutics by 354.9% in the 2nd quarter. Geode Capital Management LLC now owns 539,996 shares of the company's stock valued at $4,736,000 after acquiring an additional 421,293 shares during the last quarter. State Street Corp lifted its stake in Carisma Therapeutics by 1,325.1% in the 2nd quarter. State Street Corp now owns 475,164 shares of the company's stock worth $4,167,000 after purchasing an additional 441,821 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Carisma Therapeutics by 52.6% during the 4th quarter. Bridgeway Capital Management LLC now owns 311,034 shares of the company's stock valued at $911,000 after purchasing an additional 107,224 shares during the last quarter. 44.27% of the stock is currently owned by institutional investors.
Carisma Therapeutics Company Profile
(
Get Free Report)
Carisma Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases. The company's clinical and pre-clinical programs include CT-0508 and CT-0525 targeting HER2 overexpressing tumors; and CT-1119, a CAR-Monocyte for mesothelin overexpressing solid tumors.
Recommended Stories
Before you consider Carisma Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Carisma Therapeutics wasn't on the list.
While Carisma Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
